Article Figures & Data
Tables
- TABLE 1
Quantities, Parameters, Symbols, and Units Used in the MIRD and ICRP Dosimetry Schema (Listed in Order of Appearance in Equations 1–17)
Tissue Active bone marrow, colon, lung, stomach, breast, remainder tissues* 0.12 0.72 Gonads 0.08 0.08 Bladder, esophagus, liver, thyroid 0.04 0.16 Endosteal tissues, brain, salivary glands, skin 0.01 0.04 Total 1.00 ↵* Remainder tissues are adrenal glands, extrathoracic airways, gallbladder, heart, kidneys, lymphatic nodes, skeletal muscle, oral mucosa, pancreas, prostate (♂), small intestine, spleen, thymus, and uterus/cervix (♀). Data are taken from ICRP publication 103 (8).
Jump to section
Related Articles
Cited By...
- IL13R{alpha}2-Targeting Antibodies for Immuno-PET in Solid Malignancies
- Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
- Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
- Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
- Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
- Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition
- Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy
- MIRD Pamphlet No. 30: MIRDfit--A Tool for Fitting of Biodistribution Time-Activity Data for Internal Dosimetry
- The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE
- The MIRD Schema for Radiopharmaceutical Dosimetry: A Review
- Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy
- Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
- Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer
- Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
- Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
- MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals
- MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals
- MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry
- Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
- Dosimetric Variability Across a Library of Computational Tumor Phantoms
- The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
- Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center
- Dosimetry in Radiopharmaceutical Therapy
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
- Patient Size-Dependent Dosimetry Methodology Applied to 18F-FDG Using New ICRP Mesh Phantoms
- An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
- Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
- 11C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study
- OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry
- PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
- Human Radiation Dosimetry for Orally and Intravenously Administered 18F-FDG
- Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
- PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms
- Melanocortin 1 Receptor-Targeted {alpha}-Particle Therapy for Metastatic Uveal Melanoma
- Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation
- The Relevance of Dosimetry in Precision Medicine
- Patient-Specific Computational Model and Dosimetry Calculations for PET/CT of a Patient Pregnant with Twins
- Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors
- Whole-Body Voxel-Based Personalized Dosimetry: The Multiple Voxel S-Value Approach for Heterogeneous Media with Nonuniform Activity Distributions
- 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
- RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0
- Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
- Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues
- 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
- Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans
- Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
- Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays
- Uncertainty Quantification in Internal Dose Calculations for Seven Selected Radiopharmaceuticals
- Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
- Intratherapeutic Biokinetic Measurements, Dosimetry Parameter Estimates, and Monitoring of Treatment Efficacy Using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy
- Dose Escalation and Dosimetry of First-in-Human {alpha} Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
- MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
- Fetal and Maternal Absorbed Dose Estimates for Positron-Emitting Molecular Imaging Probes
- A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation
- Comparative Analysis of Transcriptional Gene Regulation Indicates Similar Physiologic Response in Mouse Tissues at Low Absorbed Doses from Intravenously Administered 211At
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
- A Compartmental Model for Biokinetics and Dosimetry of 18F-Choline in Prostate Cancer Patients
- Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine: Proceedings From the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank Held on February 28, 2011
- Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine: Proceedings From the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank Held on February 28, 2011
- Minimizing and Communicating Radiation Risk in Pediatric Nuclear Medicine
- An Approach for Balancing Diagnostic Image Quality with Cancer Risk: Application to Pediatric Diagnostic Imaging of 99mTc-Dimercaptosuccinic Acid
- MRI Measurement of Bone Marrow Cellularity for Radiation Dosimetry
- Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors
- Minimizing and Communicating Radiation Risk in Pediatric Nuclear Medicine
- Radiation Dosimetry of 82Rb in Humans Under Pharmacologic Stress
- Human Biodistribution and Radiation Dosimetry of 82Rb
- Dosimetry and thyroid cancer: the individual dosage of radioiodine
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study